Stockwinners Market Radar for June 10, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:41 EDT AMD CEO: We're laser focused on technology leadership - In an interview on CNBC's Mad Money, Lisa Su said AMD currently has significant scale. "Everyone needs more computing, especially high end computing, and that is our sweet spot," she added. Billions of people are using AMD's technology, and she only sees that increasing going forward. The company is still extremely focused on the data center, but there are huge opportunities in AI, she noted. Su expects a down PC market in 2022 after two years of strength. AMD is generating a lot of cash and she expects that continue.

18:00 EDT Mudrick Capital Acquisition Corp II trading resumes

17:39 EDT LHC Group, UnitedHealth receive second request for information from FTC - As previously disclosed, on March 28, LHC Group(LHCG) entered into an Agreement and Plan of Merger with UnitedHealth Group Incorporated (UNH), pursuant to which UnitedHealth Group will acquire the company. The obligation of the parties to consummate the Merger is subject to, among other things, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the Merger. As previously disclosed, on April 7, each of the company and UnitedHealth Group filed its respective notification and report form with the U.S. Department of Justice and the U.S. Federal Trade Commission under the HSR Act. As part of the parties' continuing cooperation with the Agencies and in order to provide the Agencies with additional time for review, on May 5, UnitedHealth Group, in consultation with the company, voluntarily withdrew its premerger notification and report form effective as of May 9, and then refiled the premerger notification and report form on May 11. On June 10, the company and UnitedHealth Group each received a request for additional information and documentary materials from the FTC in connection with the FTC's review of the Merger. The effect of the Second Request is to extend the waiting period imposed under the HSR Act until the 30th day after substantial compliance by the company and UnitedHealth Group with the Second Request, unless the waiting period is terminated earlier by the FTC or extended by the parties to the Merger. The parties have been working cooperatively with the FTC and will continue to do so.

17:32 EDT Mudrick Capital Acquisition Corp II trading halted, news dissemination

17:01 EDT Agnico Eagle urges shareholders to reject TRC Capital's mini-tender offer - Agnico Eagle Mines has been notified of an unsolicited mini-tender offer made by TRC Capital Investment to purchase up to 2M Agnico Eagle common shares, or approximately 0.44% of Agnico Eagle's outstanding common shares, at a price of C$64.00 per share. Agnico Eagle does not endorse this unsolicited offer, has no association with TRC Capital or its offer, and recommends that shareholders do not tender their shares to the offer. Agnico Eagle cautions shareholders that the mini-tender offer has been made at a price below the current market price for Agnico Eagle's shares. The offer represents a discount of approximately 4.51% and 4.68% to the closing price of Agnico Eagle's shares on the Toronto Stock Exchange and the New York Stock Exchange, respectively, on June 7, the last trading day before the mini-tender offer was commenced. The mini-tender offer is also subject to numerous conditions.

16:40 EDT NaaS Technology Inc. announces completion of merger - NaaS Technology Inc. (NAAS) announced the successful completion of the transaction previously announced on February 8 between RISE Education Cayman Ltd (REDU), the company's predecessor, and Dada Auto Inc. As announced on April 29, the Transaction and certain additional Transaction-related proposals were approved by RISE's shareholders at an extraordinary general meeting held on April 29. The company, with its name changed to "NaaS Technology Inc.," continues to be listed on Nasdaq with its new ticker "NAAS." Yang Wang, a founder of NaaS, has been appointed the company's CEO and a director of the company. Lei Zhao, previously the CFO of NaaS, has been appointed the chief financial officer of the company.

16:35 EDT BJ's Wholesale opens four new clubs in IN, OH, NJ, VA - BJ's Wholesale Club is continuing its expansion with the opening of four new clubs as the next phase of its 2022 development plans. BJ's brings a fresh approach to the wholesale club experience by offering members incredible value and convenience. The newest clubs will be in Noblesville, IN., New Albany, OH., Wayne, N.J., and Midlothian, V.A. "We've seen tremendous success in growing our footprint over the last several years, both in our core east coast communities as well as in new markets like the greater Detroit and Pittsburgh areas," said Bill Werner, executive vice president, strategy and development, BJ's Wholesale Club. "Our expansion into the greater Indianapolis and Columbus markets allows us to bring the value of our membership to these new communities we look forward to serving."

16:32 EDT Tesla says Larry Ellison to not seek board re-election - According to a regulatory filing, Tesla (TSLA) said that, this month, Oracle (ORCL) chairman Larry Ellison determined collectively with the Nominating and Corporate Governance Committee and the Board that he will not stand for re-election to the Board when his current term ends at the 2022 Annual Meeting. The Board currently expects to reduce the number of Board seats to seven upon the expiration of Ellison's term at the 2022 Annual Meeting, and therefore votes or proxies may not be submitted for the election of more than two board seats. The Board and the Nominating and Corporate Governance Committee will continue to frequently evaluate the optimal size and composition of the Board to allow it to operate nimbly and efficiently, while maintaining new ideas, expertise and experience among its membership.

16:19 EDT Tesla files for 3-for-1 common stock split in form of dividend - According to a regulatory filing, Tesla filed an Authorized Shares Amendment for the purpose of facilitating a 3-for-1 split of its common stock in the form of a stock dividend. As of June 6, 2022, we have 1,036,390,569 shares of common stock outstanding, and the current number of authorized shares of Tesla's common stock is 2,000,000,000, which is insufficient to effectuate the Stock Split. The company's Board intends to approve the Stock Split, subject to and contingent upon stockholder approval of the Authorized Shares Amendment.

16:16 EDT Romeo Power receives NYSE notice of non-compliance - Romeo Power announced that it received a letter from the New York Stock Exchange indicating that the company is not in compliance with the NYSE continued listing standard as set forth in Section 802.01C of the NYSE Listed Company Manual. The Letter does not result in the immediate delisting of Romeo Power's common stock from the NYSE.

16:05 EDT Virtus Investment reports preliminary AUM $167.2B as of May 31 - In addition, the company provided services to $3.2B of other fee-earning assets, which are not included in assets under management.

15:23 EDT Bluebird Bio confirms 13-0 FDA panel vote in favor of beti-cel - Bluebird Bio announced the outcome of the Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee discussion of betibeglogene autotemcel, or beti-cel, for the treatment of people with beta-thalassemia who require regular red blood cell transfusions. On the question "Do the benefits of beti-cel outweigh the risks for the treatment of subjects with transfusion-dependent beta-thalassemia?" the panel voted 13 yes to zero no. The advisory committee's recommendation is based on the Biologics License Application currently under priority review by the FDA with a decision goal date set for August 19. "Today's advisory committee recommendation is recognition of the substantial body of clinical data that support beti-cel as a potentially curative treatment option for these patients. We are grateful to the members of the beta-thalassemia community who contributed to today's discussion and remain committed to working with the FDA as it completes its review of the beti-cel Biologics License Application," said Bluebird CEO Andrew Obenshain. On June 9, the FDA panel unanimously endorsed eli-cel, an investigational gene therapy for the treatment of cerebral drenoleukodystrophy, in a 15 to 0 vote.

15:02 EDT Chicken Soup for the Soul halted for volatility after rising 18% to $8.63

14:59 EDT FDA panel backs Bluebird's beti-cel for beta-thalassemia in 13-0 vote - An FDA panel voted 13-0 that the benefits of Bluebird Bio's betibeglogene autotemcel outweigh the risks for the treatment of subjects with transfusion-dependent beta-thalassemia. Yesterday, the FDA panel voted 15-0 that the benefits of Bluebird's elivaldogene autotemcel outweigh the risks for the treatment of any sub-population of children with early active cerebral adrenoleukodystrophy. The shares remain halted.

14:24 EDT Revlon extends decline, shares now down 50% to $2.16

14:19 EDT Revlon falls 42% to $2.53 after halting for volatility

13:17 EDT MoneyGram launches crypto-to-cash service on Stellar Network - MoneyGram and the Stellar Development Foundation announced the initial roll-out of a first-of-its-kind global on/off-ramp service for digital wallets to increase the utility of digital assets by creating a bridge between cash and cryptocurrencies. The service, a result of the partnership between MoneyGram and SDF announced in October 2021, is now available in a number of key remittance markets, including Canada, Kenya, Philippines and the U.S. for the first wave of users, with global cash-out functionality expected to be available by the end of June 2022. Powered by the Stellar blockchain and Stellar-enabled digital wallets, MoneyGram's retail agent network, and Circle's USD Coin, a fully-reserved dollar digital currency, the service provides cash users access to the world of cryptocurrency via any participating MoneyGram location. This service is a monumental step towards bridging the gap between physical and digital currencies in a way that has not been done before at scale. As it develops, this solution will pave the way for blockchain technology to further financial inclusion, creating fluidity between cash and crypto so more people can benefit from the digital economy. To support adoption, MoneyGram will offer this as a zero-fee service for the first 12 months.

13:05 EDT Healthcare Capital Corp trading resumes

13:01 EDT Baker Hughes reports U.S. rig count up 6 to 733 rigs

12:35 EDT Rise Education expects Dada Auto merger to close today - RISE Education Cayman announced that it expects to close the merger between RISE and Dada Auto Inc. previously announced on February 8, 2022 after the close of trading hours for the Nasdaq Stock Market later today. As a result of the Transaction, RISE will change its corporate name to "NaaS Technology Inc." and its ticker to "NAAS." The number of the Company's shares represented by each American Depositary Share will also be changed from two shares per ADS to ten shares per ADS, which will have the same effect as a one-for-five reverse split on the existing ADSs. The CUSIP of the Company's ADSs will be changed to 62955X102. The ISIN of the Company's ADSs will be changed to US62955X1028. All of the aforementioned changes will be effective prior to 4:00 A.M. on June 13, 2022. The ADSs of the Company are expected to start trading under the new name and ticker at 4:00 A.M. on June 13, 2022.

12:00 EDT Vivint Smart Home falls -14.8% - Vivint Smart Home is down -14.8%, or -80c to $4.58.

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 9.9% - Direxion Daily Semiconductor Bear 3X Shares is up 9.9%, or $4.62 to $51.09.

12:00 EDT Daily S&P Biotech Bear 3x Shares rises 13.8% - Daily S&P Biotech Bear 3x Shares is up 13.8%, or $6.99 to $57.68.

11:22 EDT JE Cleantech Holdings Ltd trading halted, volatility trading pause

10:35 EDT Affimed presents preclinical data on AFM28 - Affimed presented a poster at the Annual Meeting of the European Hematology Association in Vienna, Austria. The data demonstrate the cytotoxic potential of the CD123/CD16A-targeting bispecific innate cell engager AFM28 which is in development as a novel treatment for patients with myeloid diseases, e. g. relapsed/refractory acute myeloid leukemia. AFM28 binds to natural killer cells and CD123-positive tumor cells and demonstrated the induction of tumor cell killing in vitro and a good tolerability and strong anti-tumor activity in vivo. The data presented at EHA provide validation of the mechanism of action as well as preclinical proof-of-concept for AFM28 in a range of in vitro and in vivo assays. AFM28 exhibited high-affinity binding to CD16A expressed on NK cells and high avidity conferring long cell surface retention in comparison to Fc-enhanced anti-CD123 antibody. Moreover, AFM28 demonstrated the ability to destroy CD123-positive tumor cell lines and primary leukemic cells via antibody-dependent cell-mediated cytotoxicity. Importantly, AFM28 was active irrespective of mutational status of tumor cells and also induced depletion when CD123 expression was very low. Strikingly, AFM28 was also active against cells not killed by an Fc-enhanced CD123-targeting comparator antibody suggesting the potential for improved clinical effectiveness. Moreover, AFM28 also depleted leukemic cells from patient bone marrow without destroying CD34-positive/CD123-negative cells, suggesting sparing of hematopoietic stem and progenitor cells. In vivo studies in an AML murine model demonstrated anti-tumor efficacy, and cynomolgus toxicology models predicted pharmacodynamic activity with a well-tolerated safety profile and low risk of cytokine release syndrome. Efficient depletion of leukemic blasts and leukemic stem cells is critical for inducing long-term remission in AML patients. As both cell types express CD123, AFM28's ability to redirect NK cells to this target killing both leukemic blasts and leukemic stem cells makes this an attractive treatment strategy. Currently, there are no curative immunotherapies available, the only option is allogenic hematopoietic stem cell transplantation. Affimed plans to initiate clinical development of AFM28 with a first-in-human phase 1 monotherapy trial in adult patients with R/R AML in the second half of 2022. In addition, Affimed plans to investigate AFM28 in combination with allogeneic NK cell therapy after a safe starting dose has been determined.

10:24 EDT UpHealth stockholders urge other stockholders not to return white proxy card - Jeffery Bray, Dr. Mariya Pylypiv, Syed Sabahat Azim, Richa Sana Azim, Dr. Azfar Malik, Alfonso Gatmaitan, Dr. Chirinjeev Kathuria and other stockholders announced today they issued an open letter urging stockholders of UpHealth to STOP, LOOK and LISTEN before taking any action in response to the Company's solicitation of proxies for the 2022 Annual Meeting of Stockholders set for 9:00 a.m. Pacific Time, on Tuesday, June 28, 2022. The stockholders said, "The UpHealth Concerned Stockholders strongly urge stockholders NOT to return the white proxy card or voting instruction form from the Company and NOT to allow the Company to take their vote over the telephone or by internet, but to wait until they receive and review the UpHealth Concerned Stockholders' definitive proxy materials and BLUE proxy card, which will be sent to UpHealth stockholders soon, before voting. If UpHealth stockholders have already voted the Company's white proxy card or voting instruction form or had their vote taken by the Company over the telephone or by internet, a later-dated BLUE proxy card will revoke their previously cast vote. When the UpHealth Concerned Stockholders' proxy solicitation materials are available, they will be seeking the vote of UpHealth stockholders because they believe that the Company needs to act now in order to restore stockholder value and do not believe that the Board, as currently constituted, and as currently proposed by the Board to be constituted following the Annual Meeting, is in the best position to achieve that objective. The Board has proposed a slate of three existing directors, adding no new viewpoints or expertise. The UpHealth Concerned Stockholders intend to solicit proxies from UpHealth stockholders to (permit them to withhold the voting of their shares at the Annual Meeting to prevent the Annual Meeting from being held until a Special Meeting of Stockholders can be held to amend the Bylaws to allow them to nominate a slate of three highly qualified independent directors and then vote those shares to elect those director nominees who the UpHealth Concerned Stockholders believe will help to enhance the value of the Company and better align the Board with the objectives of its stockholders."

10:13 EDT Senti Biosciences Inc trading resumes

10:02 EDT Izea awarded $2.8M contract by global Fortune 20 technology company - IZEA Worldwide (IZEA) announced that it has been awarded a $2.8M contract expansion by a global Fortune 20 technology company. IZEA has been contracted to execute a metaverse influencer activation inside Roblox (RBLX), with supporting activations on traditional social media platforms, including Instagram and TikTok, as well as appearances IRL.

10:00 EDT Aris Water Solutions falls -11.0% - Aris Water Solutions is down -11.0%, or -$2.33 to $18.82.

10:00 EDT ProShares UltraShort Bloomberg Natural Gas rises 5.9% - ProShares UltraShort Bloomberg Natural Gas is up 5.9%, or $1.12 to $20.16.

10:00 EDT New Oriental Education rises 14.9% - New Oriental Education is up 14.9%, or $2.19 to $16.91.

09:47 EDT Cadre falls -8.6% - Cadre is down -8.6%, or -$2.12 to $22.51.

09:47 EDT KE Holdings rises 6.3% - KE Holdings is up 6.3%, or 96c to $16.29.

09:47 EDT New Oriental Education rises 12.3% - New Oriental Education is up 12.3%, or $1.81 to $16.53.

09:42 EDT Aziyo Biologics Inc (Class A Stock) trading resumes

09:34 EDT Fulcrum Therapeutics trading halted, volatility trading pause

09:22 EDT Yandex announces terms for purchase of convertible notes - Yandex has announced that the terms of its $1.25 billion 0.75% Convertible Notes due 2025 have been amended and that it has agreed terms with the steering committee of an ad hoc group of noteholders for the purchase by Yandex and its subsidiary of Notes from participating noteholders. The Ad Hoc Group is being advised by Weil, Gotshal & Manges (London) LLP and Houlihan Lokey EMEA LLP. The indicative terms of the Purchase provide for a purchase price of $140,000 in cash and 957 Yandex Class A shares for each $200,000 in principal amount of Notes purchased. Yandex will use its commercially reasonable efforts to deliver the share consideration following the closing of the Purchase when it is permissible for the relevant shares to be delivered and received under applicable laws and regulations.The Yandex group intends to fund the cash component of the Purchase Price primarily by means of a commercial loan in compliance with Russian, United States, United Kingdom, European Union and United Nations laws and regulations. Yandex intends to implement the Purchase by way of one or more agreements with participating noteholders. Yandex expects that each Purchase Agreements will be subject to certain conditions precedent, including the agreement of all definitive documentation required to implement the Purchase, that all necessary authorisations and government approvals will have been obtained for the Purchase and that the consummation of the Purchase will not conflict with any applicable law or regulation. Yandex intends to surrender any Notes purchased by it pursuant to the Purchase to the Principal Paying, Transfer and Conversion Agent for the Notes for cancellation in accordance with the terms and conditions of the Notes. The majority of such cancellations are expected to take place immediately after completion of the Purchase, with the remainder taking place when it is permissible to do so in accordance with applicable laws and regulations.

09:20 EDT West Bancorp announces pricing of subordinated notes offering - West Bancorporation announced the pricing of its offering of $60 million of 5.25% Fixed-to-Floating Rate Subordinated Notes due 2032. The Notes will initially bear interest at 5.25% per annum, with interest payable semi-annually in arrears, commencing on the issue date, to, but excluding, June 15, 2027. Commencing June 15, 2027, the interest rate on the Notes will reset quarterly to a floating rate per annum equal to a benchmark rate that is expected to be Three-Month Term SOFR plus 241 basis points, with interest payable quarterly in arrears. The Company may redeem the Notes, in whole or in part, on and after June 15, 2027, at a price equal to 100% of the principal amount of the Notes being redeemed plus accrued and unpaid interest. The Notes will mature on June 15, 2032 if they are not earlier redeemed. The Company expects to close the transaction, subject to customary conditions, on or about June 14, 2022. The Company intends to use the net proceeds of the offering for general corporate purposes, including providing capital to support organic growth and for investing in West Bank as regulatory capital. The Notes are intended to qualify as Tier 2 capital for regulatory purposes. Piper Sandler & Co. is acting as the sole underwriter for the offering.

09:09 EDT ENG announces annual meeting results - ENG reported that the company's 2022 annual stockholders' meeting was held yesterday morning in Houston. Approximately 61% of ENG's total common stock outstanding was represented at the meeting, either in person or by proxy. Of those shares, at least 94% were cast in favor of the election of William Coskey, P.E., Mark Hess, Lloyd Kirchner, Christopher Sorrells, and Kevin Palma to a one-year term on the company's Board of Directors. Approximately 98% of the shares were cast in favor of the ratification of the appointment of Moss Adams for the fiscal year 2022 and approximately 99% of the shares were cast in favor of a non-binding "say-on-pay" advisory vote on the compensation of the above named executive officers.

09:08 EDT Activision Blizzard to recognize, begin negotiations with CWA - Activision Blizzard (ATVI) CEO Bobby Kotick today sent the following letter to all US employees: "Team, I wanted to share the news that we will begin negotiations with the Communications Workers of America, CWA, related to the 27 quality assurance employees at Raven Software, the majority of whom have chosen to be represented by this union. With the election having concluded, we will engage in good faith negotiations to enter into a collective bargaining agreement. While first labor contracts can take some time to complete, we will meet CWA leaders at the bargaining table and work toward an agreement that supports the success of all our employees... We begin this process after major investments in our QA team members over the past couple years, including significantly increasing starting pay for QA specialists and converting over 1,100 U.S.-based temporary and contingent QA workers to full-time positions. This conversion is providing access to comprehensive company benefits for QA employees and their eligible dependents." The Fly notes that Microsoft (MSFT) earlier this year agreed to acquire Activision Blizzard.

09:04 EDT Verizon reports 5G Ultra Wideband at Governors Ball Music Festival - Verizon is bringing concertgoers a new way to experience Governors Ball Music Festival this weekend with Verizon 5G Ultra Wideband. For the more than 150,000 people expected to attend the popular music festival at Citi Field in New York City, Verizon and Snap Inc. will power a transformative 5G AR experience in front of the festival's main stage. Following the first-of-its-kind Connected Lens for Super Bowl LVI, Verizon and Snap have teamed up again for a new Connected Lens experience at The Governors Ball Music Festival, a continuation of how Verizon and Snap are partnering to enhance the fan experience and future of live events. Remote Connected Lenses on Snapchat allow people to create shared AR experiences that friends can utilize together at the same time, and return to over time.

09:03 EDT CVG appoints Minja Zahirovic as president, warehouse automation - CVG announced that Minja Zahirovic has been appointed to the role of President of Warehouse Automation. This new role was created to advance the company's warehouse automation program as it continues strategic expansion in the market. Most recently, Zahirovic served as the Vice President of System Solutions at Festo North America, and prior to that held leadership and engineering positions at Irco Automation and Liburdi Engineering.

08:47 EDT Boise Cascade reaches agreement to acquire Coastal Plywood for $512M - Boise Cascade Company announced that it has reached an agreement to acquire Coastal Plywood Company, including its two manufacturing locations, from Coastal Forest Resources Company for $512M, subject to certain closing adjustments. The Company currently plans to fund the transaction and closing-related expenses from its existing cash balances. "This acquisition incrementally expands our veneer capacity in support of our customers," said Nate Jorgensen, CEO, Boise Cascade. "Near term, it provides us the ability to optimize our existing engineered wood products asset base. Longer term, we are excited to fully integrate this strategic venture and we intend to invest $50 million into our Southeast operations over a three-year period to further our EWP production capacity." The scope of this transaction does not include Coastal's parent company or timberlands assets. Closing of the acquisition is expected in the third quarter of 2022, subject to customary closing conditions, including receipt of antitrust approval under the Hart-Scott-Rodino Act of 1976, as amended.

08:35 EDT Janssen presents updated data at EHA for teclistamab - The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study. Patients in the study, including a high proportion with prior anti-CD38 monoclonal antibody exposure, achieved encouraging overall response rates, ORR, with this combination treatment. These data will be presented at the 2022 European Hematology Association, EHA, Annual Congress as an oral presentation on Sunday, 12 June. At a median follow-up of 8.6 months, 76.5 percent of response-evaluable patients enrolled in the study achieved a response, including 36 patients who achieved a very good partial response or better. In patients with prior anti-CD38 exposure, an ORR of 73.7 percent was achieved.1 The median time to first confirmed response was one month, and responses remained durable and deepened over time.1 At the analysis cut-off, 66.7 percent of patients who achieved a response were alive and continuing on therapy. The open-label, multicentre, multicohort Phase 1b TriMM-2 study is investigating the safety and efficacy of teclistamab in combination with daratumumab SC for patients with RRMM. As of April 6, 2022, 65 patients received daratumumab SC 1,800mg at the approved schedule plus teclistamab 1.5mg/kg weekly or 3mg/kg every other week subcutaneously. Pre-medications, including steroids, were limited to the two step-up doses and the first full dose of teclistamab. Treatment with the combination regimen were tolerable and no unexpected or overlapping toxicities were observed. The most common adverse events were cytokine release syndrome; neutropenia; and anaemia. One patient had Grade 1 immune effector cell-associated neurotoxicity syndrome which fully resolved. Infections were experienced by 67.7 percent of patients. Four patients died from AEs, all unrelated to teclistamab or daratumumab SC treatment. The efficacy and pharmacodynamic profile of teclistamab in combination with daratumumab SC in patients refractory to anti-CD38 therapy suggest that higher response rates may be observed in patients with anti-CD38 naive or sensitive disease who are enrolling in the MajesTEC-3 study.

08:32 EDT ABVC BioPharma announces termination of two contracts - ABVC Biopharma announced that two contracts entered into in the last 45 days have been terminated. The first of the two contracts, announced on May 3, 2022, was a $3.0 million clinical services agreement between BioKey, a wholly-owned subsidiary of the company based in Fremont, California, and NeuCen BioMed, based in Taipei, Taiwan. Under the terms of the now terminated agreement, BioKey was to be paid $3.0 million over a 3-year period to guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under U.S. FDA IND regulatory requirements. ABVC and NeuCen had also agreed, subject to further negotiation, that ABVC would loan NeuCen $1.0 million through a series of convertible debentures. The second terminated contract was between ABVC BioPharma and Orion Biotech, a Taipei-based affiliate of NeuCen. The second contract, announced on May 25, 2022, called for ABVC BioPharma to identify candidates interested in out-licensing Orion developmental products. Under the terms of this engagement, ABVC was to use its business relationships around the world to identify licensing partners for Orion products and, in return, would receive a monthly retainer fee and 15% of the licensing income and royalties received by Orion for each licensed product. The party's inability to agree to the final terms of the loan between BioKey and NeuCen led to termination of both contracts on June 6, 2022, effective immediately.

08:28 EDT Goodbody Health announces intention to delist from CSE - Goodbody Health announced its intention to de-list from the Canadian Securities Exchange and to re-domicile the Company from the Province of British Columbia to Guernsey, subject to shareholder approval. This re-domiciliation is intended to better align Goodbody's corporate structure with its current and future business activities. Goodbody has a substantial business presence in the United Kingdom and the European Union, including all of its operations, management and workforce. In addition, the fastest-growing segments of Goodbody, are currently in the United Kingdom. Goodbody does not anticipate any impact for employees, day-to-day operations, or products and services as a result of the re-domiciliation, and Goodbody intends to retain its listing on the AQSE Growth Market in London and the OTCQB in North America, which will ensure that trading in the Company's shares remains possible for both UK and North American investors. Goodbody's Board of Directors believes that the proposed plan to change its location of incorporation from the Province of British Columbia to Guernsey will provide the Company with many benefits, including: Positions the Company in proximity to a leading global financial centre and Europe's transaction hub, a location where it has substantial existing business activities and significant opportunities for continued growth; Elevates the Company's visibility among potential U.K. and other European institutional investors; Positions the Company to allow future earnings and cash flows to more efficiently fund its ongoing U.K. and European expansion; Reduces the costs and time spent procuring that the Company complies with the requirements associated with two material listings that have entirely different regulatory regimes which will allow management to focus on commercial activities; and Reduces currency risk. Shareholders will have the opportunity to vote on the proposed plan at the annual general and special meeting expected to be held in August 2022. Subject to shareholder approval, the Company anticipates that the change of the place of incorporation will become effective later in the third quarter of 2022. Shareholders' will continue to hold the exact number of shares, as they currently hold in Goodbody common shares and their shareholdings will be unchanged following the re-domiciliation. As the Company will be subject to the laws of Guernsey following the re-domiciliation, new articles of association of the Company will be adopted detailing the rights attaching to the Company's shares. With effect from the re-domiciliation, the Company's common shares will be renamed as "ordinary shares". The Company also intends to have its common shares voluntarily de-listed from trading on the CSE prior to or concurrently with the effective time of the re-domiciliation and the Company also intends that its ordinary shares will continue to be admitted to trading on the AQSE Growth Market in London. The Company expects to publish a circular to propose the CSE de-listing of the Company and re-domiciliation to Guernsey by no later than 19th July 2022, being at least 21 days prior to the expected date of the Annual General Meeting. The circular will include, amongst other things, particulars of the main differences between the Company's current constitution and the new articles to be adopted pursuant to the re-domiciliation. Goodbody is pleased to announce that it has appointed Peterhouse Capital Limited as the Company's Corporate Adviser with immediate effect.

08:25 EDT Stellantis demonstrates DWPT technology at 'Arena del Futuro' - After months of testing at the "Arena del Futuro" circuit, Stellantis, together with its project partners, demonstrated in Chiari, Italy, the capability of Dynamic Wireless Power transfer technology to wirelessly recharge electric vehicles as they travel over specially equipped, dedicated road lanes. DWPT is a system of coils positioned under the asphalt that transfers energy directly to cars, trucks and buses without the need to stop at charging stations to refill the battery. The technology can be adapted for all vehicles equipped with a special "receiver" that transfers the energy incoming from the road infrastructure directly to the electric motor, extending the range, while conserving the vehicle battery charge. The pilot project of Stellantis and all partners involved is coordinated by A35 Brebemi, a company owned by the global transportation infrastructure operator Aleatica that focuses on sustainable and innovative mobility solutions.

08:23 EDT Agenus says GSK announces interim analysis of AReSVi 006 Phase III trial - Agenus shared that partner GSK announced headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial evaluating their investigational RSV vaccine in adults aged 60 years and above. The primary endpoint was exceeded with no unexpected safety concerns observed. Engagement with regulators is planned to start immediately with anticipated regulatory submissions in H2 2022. GSK's RSV vaccine candidate contains Agenus' proprietary QS-21 STIMULON within its AS01 adjuvant, which - in the context of other antigens - has already demonstrated positive immune responses as well as a favorable safety profile. QS-21 STIMULON is a critical component of the AS01 adjuvant used in multiple GSK vaccines, including GSK's FDA approved Shingrix shingles vaccine, and the world's first malaria vaccine Mosquirix, endorsed by the WHO. Agenus' subsidiary, SaponiQx, has developed a plant cell culture method of manufacturing QS-21 STIMULON, which is designed to support its broader use based on sustainable, scalable, and cost-effective supply. SaponiQx expects to generate GMP material using this process before the end of the year to enable partner clinical trials. Once SaponiQx's plant cell culture process is fully scaled, Agenus' wholly-owned manufacturing campus is designed to support the capacity for broad use across disease settings, as well as scalability to address future pandemic threats.

08:20 EDT Eldorado announces election of directors, voting results from annual meeting - Eldorado Gold Corporation announced that all director nominees, as listed in the Management Proxy Circular dated April 25, 2022, were elected as directors of Eldorado at the Company's Annual Meeting of Shareholders held on June 9, 2022. "On behalf of the Board, we would like to thank our shareholders for their ongoing feedback and support for the governance efforts and the strategic direction we have undertaken," said Steven Reid, Chair of Eldorado Gold's Board of Directors. Further, we would like to thank George Albino, who did not stand for re-election this year, for his sound counsel and guidance during his tenure. During his five-and-a-half-years of service, George served on numerous key Board committees and was Chair during three transformative years at Eldorado, from 2018 to 2021. His guidance during this time was invaluable to the Board and Eldorado's leadership team, and he will be greatly missed. In addition, we are pleased to welcome Stephen Walker. Mr. Walker has over 35 years of experience in capital markets, focused on the mineral resource industry. Prior to his retirement from his 20-year tenure at the Royal Bank, he held varying roles, including Managing Director and Head of Global Mining Research from 2007 to 2020. Please join me in welcoming Stephen to the Board." At the Meeting, shareholders of the Company also approved: The appointment of auditors; Setting the auditor's pay; and The advisory resolution on executive compensation.

08:17 EDT VirTra granted listing extension by Nasdaq - VirTra announced today that the Company received notice from the Listing Qualifications Department of the Nasdaq Stock Market that its request for an extension to regain compliance with the Nasdaq Listing Rules has been granted. VirTra has until August 12, 2022 to file both its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Form 10-Q for the quarter ended March 31, 2022 with the U.S. Securities and Exchange Commission. VirTra expects to file the 2021 Annual Report and Form 10-Q by August 12, 2022 and regain compliance with the Nasdaq Listing Rules. As previously disclosed on April 7, 2022 and May 19, 2022 VirTra received notices from the Listing Qualifications Department of Nasdaq on April 5, 2022 and May 17, 2022, respectively, stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed its 2021 Annual Report and Form 10-Q with the U.S. Securities and Exchange Commission. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required public financial reports with the SEC.

08:15 EDT Mindset receives notice of allowance for patent covering Psilocin derivates - Mindset Pharma announced that the United States Patent and Trademark Office has issued a Notice of Allowance for Mindset's patent application number 17/387,845, titled, "Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders." The patent carries a priority date of February 4, 2020. Included within this application are several drug candidates that the Company classifies as belonging to its "Family 1" which are second-generation compounds with potential improvements compared to psilocybin in pharmacokinetics, effect size, safety, and manufacturing.

08:12 EDT Gritstone announces results from preclinical study of samRNA vaccine - Gritstone bio announced results from a preclinical study evaluating a self-amplifying mRNA vaccine candidate against SARS-CoV-2 were published in Nature Communications, in an article titled "Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection". The results of the study, which were previously pre-printed in bioRxiv, show that the samRNA vaccine candidate induced broad and potent neutralizing antibodies and T cell immune responses following administration to non-human primates at low doses, and that these immune responses were protective against SARS-CoV-2 challenge. Since the pre-publication of these data in November 2021, Gritstone disclosed initial results from a Phase 1 study of a samRNA vaccine candidate demonstrating similar outcomes against SARS-CoV-2. The company is currently evaluating samRNA vaccines for coronaviruses and other infectious diseases. Gritstone is currently evaluating four distinct SARS-CoV-2 product candidates across three different Phase 1 clinical trials containing various Spike variants plus additional highly conserved non-Spike T cell epitope sequences within its CORAL program. These studies include homologous and heterologous prime-boost regimens. All three of these studies are ongoing, and data from all are expected during the second half of 2022.

08:09 EDT Tiziana Life Sciences announces purchase of common shares by chairman - Tiziana Life Sciences announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 common shares at $0.88 per share. The acquisition takes Mr Cerrone's interests from 37.60% to 37.64%.

08:07 EDT Vincerx Pharma presents preclinical, clinical data on VIP152 in Lymphoma - Vincerx Pharma announced a poster presentation of preclinical and clinical data on VIP152, the Company's PTEFb/CDK9 inhibitor, at the European Hematology Association 2022 Congress, being held virtually and in Vienna, Austria from June 9-12, 2022. The EHA poster presents data from a high-grade B-cell lymphoma patient with a treatment-related decrease in circulating tumor TP53 mutation and preclinically demonstrates sensitivity of cells derived from chronic lymphocytic leukemia patients relapsed after ibrutinib and venetoclax to VIP152 regardless of their TP53 mutation status. The EHA poster also shares new data for 5 lymphoma patients: 3 with HGBL, 1 double expressor diffuse large B-cell lymphoma and 1 CLL patient from 2 ongoing phase 1 trials. The safety, treatment duration, pharmacokinetics, and progressive disease were pooled with 7 previously reported HGBL patients for a total of 12 lymphoma patients shown in the presentation. Key Presentation Highlights: Poster presentation, titled, "VIP152 is a novel CDK9 inhibitor with improved selectivity, target modulation, and cardiac safety in patients with lymphoma," presented by Melanie Frigault, Ph.D., Vice President of Translational Medicine, Vincerx, include: A KINOMEscan assay revealed a range of 'hits' with VIP152 compared with other CDK9 inhibitors. In depth evaluation of all potential hits was performed by Kd determination. Kd values showed VIP152 as the most selective CDK9 inhibitor in the clinic today. In the presence of low ATP, VIP152 has an IC50 value of 4.5 nM, and low nanomolar potency was also maintained in the presence of high ATP. The VIP152 IC50 of 4.5 nM was maintained for 15 to 20 hours in the plasma of patients treated at the current clinical dose of 30 mg. Therefore, VIP152 is a highly potent inhibitor of CDK9 kinase activity even in the presence of high ATP concentrations. These data show that physiologically relevant levels of VIP152 are achieved in patients with the 30-mg dose. In vitro VIP152 treatment led to the most robust downregulation of MYC mRNA expression, observed by a downregulation of 85% genes in two DLBCL cell lines, SU-DHL-4 and SU-DHL-10, compared with atuveciclib and KB-0742. Pooled cardiac safety data from 57 patients demonstrated that VIP152 does not prolong QTc interval after single or multiple doses. VIP152 cytotoxicity was evaluated in CRISPR/Cas9 edited CLL cells with homozygous TP53 mutations and showed that wild type and TP53 mutant cell lines were sensitive to VIP152 treatment at 0.5 and 1.0 microM. In vitro treatment of CLL patient-derived cells showed a concentration-dependent reduction in cell viability regardless of number of lines of prior therapy including cells from patients who had relapsed or were refractory to ibrutinib or venetoclax therapy. This presentation includes new data from five patients. The safety, treatment duration, pharmacokinetics, and progressive disease were pooled with 7 previously reported HGBL patients for a total of 12 lymphoma patients shown in the presentation. Duration of treatment for this cohort ranges from 2 weeks to over 3 years. Of the 12 total treated patients, five were evaluable for best overall response. Of these, two patients with double-hit DLBCL achieved complete remission and remain in remission nearly two years after stopping therapy, while others stopped treatment due to clinical or radiographic progression; and, in one case due to investigator decision. The absolute neutrophil count was measured at each treatment visit. Our data show that once weekly dosing of VIP152 allows for the recovery of neutrophils before the next dose. Neutropenia was considered monitorable and manageable with supportive care. Blood-based PD effect showed a robust down-modulation of MYC, MCL1 and PCNA mRNA in all 11 patients analyzed. Circulating tumor DNA changes were monitored in three newly reported patients. In one patient, ctDNA reduction in TP53 mutation, and in CDK6 and MYC copy number was observed after three weeks of VIP152 treatment. ctDNA is currently being investigated as a non-invasive tool to aid with predicting outcomes to treatment in patients with high-risk B-cell lymphoma. Clinical evaluation of VIP152 is currently ongoing in two phase 1 trials in patients with solid tumors or aggressive NHL, and with CLL and Richter Syndrome.

08:05 EDT Eurofins J3 Resources expands AIHA LAP certification for industrial hygiene - Eurofins J3 Resources, part of Eurofins Built Environment Testing US, announces it has been granted AIHA LAP accreditation as part of a National expansion program of Industrial Hygiene credentials. Eurofins J3 Resources' industrial hygiene service offering to Texas, Louisiana and Gulf Coast based refineries and chemical plants has been extended to now include rapid turnaround time, media/pump supplies and on-staff Certified Industrial Hygienists. The extension to the Eurofins J3 Resources service offering means it now comprises of BTEX and other organics, hexavalent chromium as well as detection of welding fumes and other metals. The expanded accreditation includes NIOSH 1003 Modified, NIOSH 1501 Modified, AT Organic Vapor Analytical Method Modified, SKC 575 Series Passive Sampler Method Modified for Volatile Organic Compounds in air; NIOSH 7303 Modified for metals in air; and OSHA ID-215 Modified for hexavalent chromium.

08:04 EDT Vor Bio demonstrates multiplex editing of hematopoietic stem cells - Vor Bio announced dual editing of CD33 and CLL-1 in human hematopoietic stem cells demonstrating continued progress on its novel approach for the treatment of acute myeloid leukemia. The data is being presented at the European Hematology Association Congress in Vienna, Austria. The pre-clinical data demonstrates that multiplex deletion by CRISPR/Cas9 of CD33 and CLL-1 from human CD34+ hematopoietic stem and progenitor cells maintained cell function and persisted long-term post engraftment in vivo, with a high-level of editing, no counterselection, and minimum translocation risk when compared to unedited control cells. In addition, genetically modifying HSPCs to remove select cell surface targets does not impair their function and these dual engineered cells showed significant protection from targeted immunotherapy in vitro. AML is the most common type of acute leukemia in adults and is characterized by excessive proliferation of immature myeloid progenitor cells and their failure to properly differentiate into mature blood cells. Healthy donor HSC transplantation is the standard of care and currently around 40% of patients with AML who receive HSC transplantation suffer a relapse of their cancer, with two-year survival rates of less than 20%, highlighting the need for new therapeutic approaches for these patients. Vor Bio is developing a first-in-class treatment approach consisting of gene-edited HSC transplants that are designed to be resistant to targeted therapies, enabling post-transplant use of powerful therapies such as CAR-Ts or other targeted immuno-therapies. This new approach has the potential to protect healthy cells from the damaging effects of cancer-targeted therapies, leaving the cancerous cells exposed and, for the first time, allowing these targeted therapies to be truly cancer-specific sparing the healthy cells.

08:03 EDT Manning & Napier reports preliminary AUM $19.4B as of May 31 - Compared with $19.6 B at April 30 and $20.6B at March 31.

08:01 EDT Activist Investing discloses 9.9% ownership interest in Titan Pharmaceuticals - David Lazar, CEO of Activist Investing, one of the largest stockholders of Titan Pharmaceuticals, with 9.9% of the Company's outstanding shares, issued the following statement: "As disclosed in our initial Schedule 13D filing in April 2022, we continue to engage in discussions with the Board of Directors and management concerning the Company's strategic alternatives. As a result of our belief in the prospects of the Company and its ability to unlock significant stockholder value through a strategic transaction, we filed an amendment to our Schedule 13D yesterday disclosing an increase in our already sizeable position in the Company to 9.9% of TTNP's outstanding shares. We remain hopeful that the Company's strategic review will result in a positive outcome that is in the best interest of all TTNP stockholders."

07:44 EDT Fusion Pharmaceuticals, Niowave announce actinium-225 supply agreement - Fusion Pharmaceuticals and Niowave, a manufacturer of medical radioisotopes from radium and uranium, announced that the companies have entered into a collaboration and supply agreement for the development, production, and supply of actinium-225. Under the agreement, Fusion will invest up to $5M in Niowave to further develop their technology to increase current production capacity of actinium-225, and in return Fusion will have guaranteed access to a pre-determined percentage of Niowave's capacity of the resulting actinium-225, as well as preferred access to any excess supply produced. As part of the agreement, Fusion will also have an option to invest in future production of actinium-225 to scale with Fusion's needs.

07:34 EDT BridgeBio affiliate Venthera presents preliminary results from VT30 trial - BridgeBio Pharma and its affiliate company Venthera announced preliminary data from the Phase 1b trial of VT30 topical gel in patients with venous, lymphatic and mixed venolymphatic lesions of the skin, which are rare genetic vascular anomalies driven by dysregulated activation of intracellular PI3K. The data are being shared in a virtual presentation to the International Society for the Study of Vascular Anomalies. The data presented are preliminary results from an open-label, dose-finding study of VT30 topical gel in patients with cutaneous VM/LM/VLM lesions associated with mutations that result in dysregulated PI3K activation. VT30 topical gel is designed to potently inhibit PI3K in the treated tissue without systemic side effects. Early findings include: Across 15 subjects treated in escalating-dose cohorts, VT30 topical gel has been generally well-tolerated; local self-limited rash was the only adverse experience of note, occurring at an increased incidence with the highest gel concentration. All reported adverse experiences were characterized as mild to moderate. Pharmacokinetic and pharmacodynamic skin punch biopsies were taken from within the lesion. These data demonstrate that high concentrations of drug are present in the lesion at day 28 and show a reduction of pS6 in the lesion from baseline to day 28. No circulating drug was detected in plasma with any of the gel strengths studied. Based on the findings shared during ISSVA 2022, Venthera has tentatively selected the 0.6% gel for further study. Venthera is currently seeking partners to support development of VT30 topical gel in Phase 2.

07:31 EDT Zai Lab announces breakthrough therapy designation for repotrectinib in China - Zai Lab announced that the Center for Drug Evaluation of the National Medical Products Administration granted two Breakthrough Therapy Designations for investigational repotrectinib for the treatment of patients with ROS1-positive metastatic NSCLC who have received one prior line of ROS1 TKI and one prior line of platinum-based chemotherapy and for those with ROS1-positive metastatic NSCLC who have received one prior line of ROS1 TKI and no chemotherapy or immunotherapy. The Breakthrough Therapy Designations for repotrectinib were supported by the data from both global and Chinese TKI-pretreated ROS1-positive NSCLC patients enrolled in the Phase 1/2 TRIDENT-1 study.

07:18 EDT BeiGene presents data from its hematology portfolio at EHA 2022 - BeiGene presents data from its hematology portfolio at the European Hematology Association, EHA, 2022 Hybrid Congress being held June 9-12, 2022, in Vienna, Austria. Highlights from the broad clinical program for zanubrutinib presented at EHA include: ASPEN: Long-term safety and efficacy results from the Phase 3 ASPEN trial of zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia, WM, showed that, at a median follow up of 43 months, zanubrutinib continued to demonstrate clinically meaningful efficacy and a tolerable safety profile in patients with WM. ROSEWOOD: The Phase 2 ROSEWOOD trial of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma met its primary endpoint of overall response rate and was generally well-tolerated, with safety results consistent with previous studies of both medicines. ALPINE: In the head-to-head ALPINE trial of zanubrutinib versus ibrutinib in patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma, those who received zanubrutinib monotherapy reported improvements in key health-related quality of life, HRQoL endpoints compared with patients who received ibrutinib monotherapy. SEQUOIA: In the SEQUOIA trial of zanubrutinib vs. bendamustine plus rituximab, zanubrutinib was associated with significant improvements in HRQoL in patients with treatment-naive CLL/SLL without del, as indicated by patient reported outcome, PRO, endpoints. The ROSEWOOD and ASPEN study findings were presented at the American Society of Cancer Oncology Annual Meeting in June 2022. BeiGene also presented two posters from proof-of-concept studies of BGB-11417, a highly selective investigational BCL2 inhibitor in CLL, non-Hodgkin's lymphoma and acute myeloid leukemia. Preliminary data from an ongoing Phase 1/1b dose-escalation and expansion study evaluating the safety, tolerability, maximum tolerated dose, and recommended Phase 2 dose of oral BGB-11417 as monotherapy or in combination with zanubrutinib, in patients with B-cell malignancies, showed promising efficacy potential for BGB-11417 and an improved safety profile, particularly in combination cohorts. Preliminary data from an ongoing Phase 1b/2 global, multi-center dose escalation and expansion study evaluating BGB-11417 plus azacytidine in patients with AML demonstrated the combination to be generally well-tolerated with the majority of complete responses observed by the end of Cycle 1.

07:13 EDT Gamida Cell appoints Borrello to board of directors - Gamida Cell (GMDA) announces the appointment of Ivan Borrello, M.D. to its Board of Directors, effective June 9, 2022. Borrello is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The Company also announces the resignation of Ofer Gonen from its Board of Directors, effective June 9, 2022. Gonen will be joining MediWound (MDWD) as chief executive officer effective June 30, 2022.

07:11 EDT BeiGene announces China NMPA approves tislelizumab - BeiGene announced that the China National Medical Products Administration, NMPA, has approved BeiGene's anti-PD-1 antibody, tislelizumab, in combination with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer, NPC. "NPC is one of the most common head and neck cancers in China and many parts of Asia. Treatment options have been limited, with chemotherapy primarily provided for front-line care. On behalf of these patients, today's approval of tislelizumab, a potentially differentiated checkpoint inhibitor, for patients with recurrent or metastatic NPC could provide new hope," commented Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. "We look forward to bringing this important immunotherapy to the underserved patient community in China." This approval was supported by clinical results from the randomized, double-blind, Phase 3 clinical trial RATIONALE 309 to evaluate the efficacy and safety of tislelizumab combined with gemcitabine and cisplatin versus placebo combined with gemcitabine and cisplatin as a first-line treatment for patients with recurrent or metastatic NPC.

07:10 EDT Cogent Biosciences announces initial clinical data from Phase 2 APEX trial - Cogent Biosciences announced positive initial data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis. The data are being presented today in a poster presentation at the 2022 European Hematology Association Congress in Vienna, Austria. APEX is a global, open-label, multi-center, two-part Phase 2 clinical trial in patients with AdvSM evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. As of the data cutoff date of May 24, 2022, 11 patients had been treated in Part 1 at one of four dose levels. The median age of patients at study entry was 70 years. Patients were enrolled with the following sub-types: two patients with aggressive systemic mastocytosis, eight patients with systemic mastocytosis with associated hematologic neoplasm, and one patient with mast cell leukemia. Two patients had received prior avapritinib and midostaurin treatment. As of the cutoff date, May 24, 2022, bezuclastinib was generally well-tolerated at all doses. The majority of adverse events were Grade 1/2 and seen in no more than one patient with one serious adverse event and no Grade 4 events reported. Grade 3 events reported as at least possibly related were anemia, neutropenia and hypersensitivity/mediator flare. There were no reported cases of periorbital/peripheral edema, cognitive effects or intracranial bleeding events, which have been associated with other KIT inhibitors. As of the cutoff date, all patients remained on study. Subsequently, one SM-AHN patient with chronic myelomonocytic leukemia transformed to acute myeloid leukemia and discontinued participation in the trial. As of the data cutoff date of May 24, 2022, all 11 patients treated were evaluated for signs of clinical activity. Eight of 11 patients had been treated for at least two cycles, had available data from bone marrow biopsy, and were evaluated for additional endpoints Cycle 3 Day 1 evaluable. 11/11 patients achieved greater than or equal to50% reduction in serum tryptase levels by central assessment; 89% median reduction in serum tryptase; Six of these patients achieved reduction to less than20 ng/mL; 8/8 patients achieved greater than or equal to50% reduction in bone marrow mast cells by central review; Six of these patients achieved complete clearance of bone marrow mast cell aggregates; 8/8 patients demonstrated decreases in KIT D816V variant allele fraction by droplet digital polymerase chain reaction; All patients remained on treatment with treatment duration ranging from 0.5 - 4.8 months. Two patients enrolled had previously received and discontinued avapritinib for toxicity reasons. Both patients have demonstrated clinical outcomes consistent with the avapritinib-naive patients, including similar magnitude reductions in serum tryptase. Based on the favorable initial safety and tolerability profile and clinical activity observed to date in the Phase 2 APEX clinical trial with bezuclastinib for AdvSM,Cogentwill continue enrolling patients in Part 1 of APEX to determine a recommended dose for use in Part 2 of the trial. A pre-planned interim analysis is scheduled once approximately 28 patients have received at least two cycles of study treatment in Part 1. Cogent plans to present additional data from APEX by the end of 2022. In addition,Cogent continues to actively enrollpatients in SUMMIT, a Phase 2 clinical trial with bezuclastinib for NonAdvSM, and PEAK, a registrational randomized, open-label, global, Phase 3 clinical trial in patients with imatinib-resistant Gastrointestinal Stromal Tumors. Cogent plans to present initial data from SUMMIT and lead-in data from PEAK in the first half 2023.

07:07 EDT Cyclerion Therapeutics announces clinical data from study of CY6463 - Cyclerion Therapeutics announced positive topline data in its signal-seeking clinical study of CY6463, for the potential treatment of Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes. Chad Glasser, Pharm.D., Director of Clinical Research at Cyclerion Therapeutics, will present results from this clinical study today during the Clinical Trial Updates Panel at the United Mitochondrial Disease Foundation Mitochondrial Medicine 2022 Symposium, taking place June 8-11, 2022, in Phoenix, Arizona. CY6463 is a positive allosteric modulator of soluble guanylate cyclase, which amplifies endogenous NO signaling, a pathway that has been linked to mitochondrial biogenesis and function. In this open-label, single-arm study of the oral, once-daily sGC stimulator in eight MELAS patients, improvements were seen across a range of biomarkers, including mitochondrial disease-associated biomarkers such as lactate and GDF-15, a broad panel of inflammatory biomarkers, cerebral blood flow, and functional connectivity between neural networks. These positive effects after 29 days of dosing were supported by correlations across several endpoints and were more pronounced in patients with greater baseline disease burden. A return toward baseline levels after discontinuation of CY6463 dosing across several biomarkers was also observed. CY6463 was well tolerated with no adverse events leading to treatment discontinuation, and pharmacokinetics were consistent with the Phase 1 study in healthy volunteers. The positive data from this study further support the potential of CY6463, the first and only CNS-penetrant sGC stimulator in clinical development, to provide therapeutic benefit to people living with MELAS. Study Highlights: The single-arm, open-label study enrolled eight participants who spanned a range of disease burden; 6 of the 8 were also taking a daily regimen of oral arginine or citrulline, precursors to nitric oxide that are current standard of care for MELAS patients. CY6463 was well tolerated; there were no reports of serious adverse events or treatment discontinuation due to adverse events. The PK profile and concentrations in the cerebrospinal fluid and plasma were consistent with exposures observed in Phase 1 healthy volunteer studies. Effects were observed across multiple domains of disease activity: Improvements in biomarkers associated with mitochondrial function including lactate and GDF-15. These changes correlated with each other and with CY6463 plasma concentrations; Improvements across a broad panel of inflammatory biomarkers; Increases in cerebral blood flow across all brain regions. These changes correlated with clinical improvement as assessed by the patient global impression of change scale; Increases in functional connectivity between brain regions and activation of occipital brain regions in response to the visual stimulus as measured by fMRI BOLD.

07:04 EDT CTI BioPharma presents data from pacritinib program at EHA - CTI BioPharma announced two scientific poster presentations from the company's pacritinib clinical program at the European Hematology Association 2022 Congress, being held in Vienna, Austria, June 9-12. "Our presentations today demonstrate that full dose pacritinib achieved higher response rates and a similar, manageable safety profile compared to lower-dose ruxolitinib in patients with myelofibrosis who have moderate or severe thrombocytopenia," said Adam Craig, President and CEO of CTI BioPharma. "As the commercial launch of VONJOTM (pacritinib) in the U.S. continues to exceed our expectations, we are pleased to highlight VONJO's clinical value as a potential best in class treatment for patients with cytopenic myelofibrosis with platelet counts below 50 109/L."

07:02 EDT China Liberal Education to acquire Oriental Wisdom Cultural Development Co. - China Liberal Education announced that on June 9, the company, through its wholly-owned subsidiary, China Liberal Education Technology Co., Ltd., entered into a definitive stock purchase agreement with Beijing Cloud Class Technology Co., Ltd. to acquire from Cloud Class 100% of the issued equity interests of Beijing Oriental Wisdom Cultural Development Co., Ltd., an integrated education service provider focusing on operating jointly-managed academic programs in the vocational higher education industry in China. This acquisition is a critical initiative of the company's business strategy of boosting the Company's development in the vocational education industry through integrating enterprises and developing vocational education across various industries. Pursuant to the Agreement, China Liberal Beijing agrees to acquire 100% of the equity interests of Oriental Wisdom from Cloud Class in consideration of 7M ordinary shares of the company, subject to certain payment schedules set forth in the Agreement. The transaction contemplated by the Agreement has been approved by the company's board of directors at a special meeting on June 1, with the closing expected to occur near the end of June.

06:49 EDT Altair announces pricing of offering of $200M convertible senior notes - Altair announced the pricing of $200 million aggregate principal amount of Convertible Senior Notes due 2027 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Altair also granted the initial purchaser of the notes a 13-day option to purchase up to an additional $30 million aggregate principal amount of notes. The sale of the notes to the initial purchaser is expected to settle on June 14, 2022, subject to customary closing conditions, and is expected to result in approximately $194.6 million in net proceeds to Altair after deducting the initial purchaser's discounts and commissions and estimated offering expenses payable by Altair. The notes will be senior, unsecured obligations of Altair. The notes will bear interest at a rate of 1.750% per year, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2022. The notes will mature on June 15, 2027 unless earlier repurchased, redeemed or converted. Altair may not redeem the notes prior to June 20, 2025. Altair may redeem for cash all or, subject to certain limitations, any portion of the notes, at its option, on or after June 20, 2025 if the last reported sale price of Altair's Class A Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which Altair provides notice of redemption, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. The notes will be convertible at an initial conversion rate of 13.9505 shares of Altair's Class A Common Stock, per $1,000 principal amount of notes. Prior to the close of business on the business day immediately preceding December 15, 2026, the notes will be convertible at the option of the noteholders only upon the satisfaction of specified conditions and during certain periods. On or after December 15, 2026 until the close of business on the business day immediately preceding the maturity date, the notes will be convertible at the option of the noteholders at any time regardless of these conditions. Upon conversion, Altair will satisfy its conversion obligation by paying and/or delivering, as the case may be, cash, shares of its Class A Common Stock or a combination of cash and shares of its Class A Common Stock, at Altair's election. Altair intends to use approximately $192.4 million of the net proceeds from the offering to repurchase approximately $148.2 million aggregate principal amount of Altair's 0.250% Convertible Senior Notes due 2024 in the repurchase transactions described below and to use the remainder of the net proceeds for working capital and other general corporate purposes, which may include potential acquisitions and strategic transactions as well as repurchases of its Class A Common Stock. From time to time, Altair evaluates potential acquisitions and strategic transactions of businesses, technologies, or products. However, Altair has not designated any specific uses and has no current agreements with respect to any material acquisition or strategic transaction. Altair's intentions with respect to its use of such net proceeds are subject to change. Contemporaneously with the pricing of the notes, Altair entered into separate privately negotiated transactions with certain holders of the 2024 notes to repurchase approximately $148.2 million aggregate principal amount of the 2024 notes for an aggregate of approximately $192.4 million of cash. Altair expects that certain holders of 2024 notes that agreed to sell their 2024 notes in negotiated transactions with Altair will, concurrently with or shortly after the pricing of the notes, enter into or unwind various derivatives with respect to Altair's Class A Common Stock and/or purchase shares of Altair's Class A Common Stock in the market. The amount of Altair's Class A Common Stock that such holders purchase may be substantial in relation to the historic average daily trading volume of Altair's Class A Common Stock. In addition, Altair expects that certain purchasers of the notes may establish a short position with respect to Altair's Class A Common Stock by short selling Altair's Class A Common Stock or by entering into short derivative positions with respect to Altair's Class A Common Stock, in each case, in connection with the offering.

06:46 EDT Lazard reports preliminary AUM $236B as of May 31 - Lazard reported that its preliminary assets under management as of May 31 totaled approximately $236B. The month's AUM included foreign exchange appreciation of $1.4B, market depreciation of $1.1B, and net outflows of $1B.

06:35 EDT Four Seasons Education announces change to ADS ratio - Four Seasons Education announced that it will change the ratio of its American depositary shares representing its ordinary shares from two ADSs representing one ordinary share to one ADS representing ten ordinary shares. For Four Seasons Education's ADS holders, the change in the ADS ratio will have the same effect as a one-for-twenty reverse ADS split. There will be no change to the Company's underlying ordinary shares, and no ordinary shares will be issued or cancelled in connection with the change in ADS ratio. The Company will file a post-effective amendment to its registration statement on Form F-6 with the United States Securities and Exchange Commission to reflect the change in the ADS ratio. The effect of the ratio change on the Company's ADS trading price on the New York Stock Exchange is expected to take place on or about June 21, 2022. Each ADS holder of record at the close of business on the date when the change in the ADS ratio is effective will be required to surrender their ADSs to the Company's depositary bank, Deutsche Bank Trust Company Americas, for cancellation and exchange in the ratio of every twenty existing ADSs for one new ADS. Four Seasons Education's ADSs will continue to be traded on the NYSE under the symbol "FEDU".

06:33 EDT ChromaDex signs distribution agreement with Sinopharm Xingsha - ChromaDex announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen into mainland China. Tru Niagen features ChromaDex's proprietary Niagen ingredient, which is the world's most efficient NAD+ precursor on the market, particularly over NMN. Sinopharm Xingsha is the main platform of Sinopharm Group for food supplements and healthcare products and is a subsidiary of Sinopharm Group, with businesses including pharmaceutical manufacturing, marketing and distribution of drugs, and food supplements and healthcare products. Sinopharm Group is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission of the State Council, with a full value chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business, and financial services. In line with ChromaDex's recent China Joint Venture announcement, Sinopharm Xingsha will collaborate to secure Health Food Registration in China.

06:22 EDT Keros Therapeutics reports results from KER-050 Program - Keros Therapeutics announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes, as well as preclinical data on the differentiated mechanism of action of KER-050 and its activity on multiple stages of thrombopoiesis, at the 27th Annual Congress of the European Hematology Association, held in person and virtually June 9 through 17, 2022. In addition, Keros announced preclinical data evaluating ALK2 inhibition as a potential treatment option for anemia of inflammation. "We believe the additional data from our ongoing Phase 2 clinical trial of KER-050 in MDS patients continues to support the potential of KER-050 as a treatment for multilineage cytopenias, and are pleased to present at EHA this year," said Jasbir S. Seehra, Ph.D., President and CEO of Keros. "Additionally, we are excited to announce that we have recently initiated dosing for Part 2 of the trial, at a starting dose of 3.75 mg/kg, with an opportunity for patients to dose escalate to 5.0 mg/kg based on individual titration rules, following the Safety Review Committee recommendation for this trial." Sustained increases in platelets were observed in HTB patients achieving HI-E or TI, which supports the potential of KER-050 as a treatment for multilineage cytopenias in difficult-to-treat HTB patients. Increases in reticulocytes and serum soluble transferrin receptor levels, as well as decreases in serum ferritin, were also observed in HTB patients. Together, these exploratory pharmacodynamic data suggest an improvement in erythropoiesis. As of the data cut-off date, KER-050 was observed to be generally well-tolerated in the 31 patients in Cohorts 1 through 5 who had received at least one dose of KER-050. No drug-related serious adverse events or dose-limiting toxicities were reported. The most commonly reported treatment-emergent adverse events were dyspnea, fatigue, anemia, diarrhea, headache and nausea. Treatment-related adverse events were reported in five patients, which were mild or moderate in severity. No patients developed acute myeloid leukemia. Four patients withdrew from the trial prior to completing treatment with KER-050, one due to death deemed unrelated to study drug, one due to withdrawn consent and two due to unrelated treatment-emergent adverse events. Following recommendation by the Safety Review Committee, dosing for Part 2 of the trial was initiated at a starting dose of 3.75 mg/kg, with an opportunity for patients to dose escalate to 5.0 mg/kg based on individual titration rules.

06:12 EDT Caribou Biosciences presents data from ANTLER Phase 1 trial for CB-010 - Caribou Biosciences announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Following a single dose at the initial dose level of CB-010, a 100% complete response rate was observed as best response. At 6 months following the single dose of CB-010, 40% of patients remained in CR as of the May 13, 2022 data cutoff date. The data are being presented at the European Hematology Association 2022 Hybrid Congress, being held in Vienna, Austria, June 9-17, 2022. "The preliminary safety and efficacy results are promising. All six patients treated with CB-010 at the initial dose level of 40 million CAR-T cells achieved a complete response, and we are now enrolling dose level 2 and look forward to seeing this study mature," said Loretta J. Nastoupil, M.D., associate professor, Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and the presenting investigator on the ANTLER trial. "CB-010 was generally well-tolerated and the adverse events observed are consistent with autologous or allogeneic CAR-T cell therapies."

06:08 EDT Global Blood Therapeutics presents data supporting use of Oxbryta - Global Blood Therapeutics announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta for the treatment of sickle cell disease in patients 12 years of age and older. In addition, Phase 1 data of GBT021601, the company's next-generation sickle hemoglobin polymerization inhibitor, support its progression into the Phase 2 portion of a Phase 2/3 trial that is anticipated to commence by mid-year. These data, as well as new research from the United Kingdom demonstrating that an improvement of anemia as measured by hemoglobin reduces the risk of end-organ damage in SCD patients, will be presented at the European Hematology Association 2022 Hybrid Congress from June 9-12, 2022 in Vienna, Austria and online. "At EHA2022 this week, we presented data from the first multicenter retrospective study of SCD patients treated with Oxbryta in a real-world setting, which demonstrated the positive clinical impact of Oxbryta - results that were consistent with the pivotal Phase 3 HOPE Study. In addition, our study in the U.K. of the impact of the improvement of anemia adds to the growing body of data that supports the need to maximize hemoglobin levels in sickle cell patients in order to help protect against end-organ damage," said Ted W. Love, M.D., president and chief executive officer of GBT. "As more clinicians gain experience with Oxbryta and we build on our recent regulatory approvals by the European Commission and in the Middle East, we're very pleased with our progress on making this transformative, first-in-class therapy available to more patients around the world."

06:05 EDT Coty announces intention to gradually recommence shareholder returns - Coty announced its intention to gradually return its Equity distributions as deleveraging continues, while also entering into agreements with several banks to start hedging a planned $200M share buyback program in calendar 2024. Having made substantial progress in lowering its leverage from ~7x exiting FY21 to 4.7x exiting 3Q FY22, or approximately 3.6x when factoring in the value of its retained 26% stake in Wella, Coty anticipates continued strong free cash flow generation and steady deleveraging progress in the coming years. As Coty progresses on its trajectory to reach its targeted leverage of approximately 2x by calendar 2025, this will open opportunities for Coty to gradually recommence shareholder distributions, within the scope of the Ccompany's financial policy. Coty has therefore entered into total return swaps in respect of its Class A Common Stock with several banks to hedge its potential exposure at around prevailing stock price trading levels over the applicable hedging periods for a planned $200M share buyback program. Any total return swap settled in shares would be covered by the company's existing share repurchase authorization.

06:03 EDT Amarin: UK's NICE recommends reimbursement, use of VAZKEPA - Amarin announces that the UK's National Institute for Health and Care Excellence is recommending icosapent ethyl, marketed under the brand name VAZKEPA, for reimbursement and use across the National Health Service in England and Wales to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides, LDL-C levels greater than1.04 mmol/L, and established cardiovascular disease, at a price of GBP 144.21 per 120 soft capsules.

05:57 EDT Imago BioSciences reports 'positive' data from Phase 2 study of bomedemstat - Imago BioSciences presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia. Updated Highlights: Enrollment completed with 73 patients in April 2022. Of the 32 patients treated with bomedemstat for more than 24 weeks: 97% achieved platelet count reduction to less than or equal to400 x 109/L. 94% achieved platelet count reduction to less than or equal to400 x 109/L with no thromboembolic events, the primary efficacy endpoint of this study. 81% of patients achieved a durable response, defined as platelet count of less than or equal to400 x 109/L for at least 12 weeks. Of the 31 patients with Total Symptom Score data available at 24 weeks: 58% showed a decrease in TSS. 32% showed improvements greater than or equal to10 points, one component of the ELN criteria for response. Importantly, platelet response rates were similar across all genotypes identified in the study. Additionally, 67% patients demonstrated a net decrease in mutation allele frequencies including both CALR and JAK2.

05:52 EDT AbbVie presents new data from Cohort 3 of Phase 2 REFINE study - AbbVie announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naive patients with myelofibrosis, a rare and difficult to treat blood cancer. These preliminary findings show spleen volume and symptomatic improvement in this cohort. These data are consistent with previously observed data from relapsed/refractory patients in Cohort 1a1 and will be shared in an oral presentation at the 2022 European Hematology Association Annual Congress. REFINE is a Phase 2 non-randomized open-label multi-cohort study evaluating the safety and efficacy of navitoclax alone or in combination with ruxolitinib in MF.

05:48 EDT Copa Holdings reports preliminary May traffic down 4.2%, capacity down 3.7% - Load factor was down 0.4 p.p. Given the irregular nature of the company's operations starting in March 2020 due to the Covid-19 pandemic, this traffic report will compare to 2019 statistics. Consolidated capacity came in 3.7% lower than May 2019, while passenger traffic decreased 4.2%, which resulted in an 85.7% load factor.